건강한 한국인 자원자에서 테오브로민(Theobromine) 500mg 캡슐 반복 투여에 의한 안전성 및 약동학 평가에 관한 연구

Safety and Pharmacokinetics of Theobromine after Multiple Adminstrations in Healthy Volunteers

  • 김정원 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 신광희 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 이소정 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김태은 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 오세을 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 윤서현 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 조주연 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 유경상 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 신상구 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과)
  • Kim, Jung-Won (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Shin, Kwang-Hee (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yi, So-Jeong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Kim, Tae-Eun (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Oh, Se-Ul (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yoon, Seo-Hyun (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Cho, Joo-Youn (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Shin, Sang-Goo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
  • 투고 : 2010.02.09
  • 심사 : 2010.06.10
  • 발행 : 2010.06.30

초록

Background: Theobromine (3,7-dimethylxanthine) has various clinical properties including vasodilation, bronchodilation, and diuresis in humans. It is currently under clinical investigation for cough suppression. The aim of this study was to evaluate the safety and pharmacokinetic characteristics after multiple oral administrations of theobromine 500 mg capsules in healthy male volunteers. Methods: A single-arm, multiple-dosing study was conducted in 12 healthy male volunteers. All subjects orally received the study drug every 12 hours for 7 days. Blood samples were collected up to 12 hours after first dosing and up to 48 hours after last dosing. Plasma concentrations of theobromine were analyzed using high-performance liquid chromatography. Safety assessments, including monitoring adverse events, laboratory tests, vital signs, ECGs, and physical examinations, were performed throughout the study. Results: Pharmacokinetic steady-state was achieved before the last dosing. Median time to peak concentration at steady state ($T_{max,ss}$) was 1.8 hr. Mean terminal half-life was 13.4 hr, and mean peak-trough fluctuation was 47.5% at steady state. At steady state, mean peak concentration ($C_{max,ss}$) and area under the plasma concentration-time curve during a dosing interval ($AUC_{\tau,ss}$) was $22.0\;{\mu}g/mL$ (coefficient of variation, CV: 13.8%) and $213.9\;{\mu}g{\ast}h/mL$ (CV: 17.6%), respectively. Mean accumulation ratio ranged from 1.8 to 2.8 after multiple administrations. There were neither any serious adverse events nor remarkable findings regarding safety. Conclusion: Theobromine capsules were safe and well-tolerated when administered twice daily at dose of 500 mg for 7 days. This study showed the relatively low inter-individual variation in terms of $C_{max}$ and AUC, and moderate accumulation after multiple dosing. This study provided evidence for a twice-a-day dosing regimen of theobromine 500 mg capsules for treatment of chronic cough.

키워드

참고문헌

  1. Cho SH. Cough. The Korean Journal of Medicine, 2009;76(3):252-259.
  2. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis, 1990;141(3):640-647. https://doi.org/10.1164/ajrccm/141.3.640
  3. Pavesi L, Subburaj S, Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest, 2001;120(4):1121-1128. https://doi.org/10.1378/chest.120.4.1121
  4. Resine T, and Pasternak, G. Goodman and Gilman's the pharmacological basis of therapeutics, 6th ed.; 1996.
  5. Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA, Korbonits M, Korbonits D, Barnes PJ. Theobromine inhibits sensory nerve activation and cough. FASEB J, 2005;19(2):231-233.
  6. Dicpinigaitis PV. Currently available antitussives. Pulm Pharmacol Ther, 2009;22(2):148-151. https://doi.org/10.1016/j.pupt.2008.08.002
  7. THOMSON. MICROMEDEX. Available at:http://ccis.snuh.org/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/518271/DUPLICATIONSHIELDSYNC/94D102/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/0012/ContentSetId/31/SearchTerm/theophylline%20/SearchOption/BeginWith.
  8. KORBONITS D, ARaNYI P, JELINEK I, MIKUS E. ANTITUSSIVE COMPOSITIONS, WO/1998/042322, 1997.